News for Phathom Pharmaceuticals, Inc. (PHAT)

North Carolina-based Chimerix, Inc. (CMRX) is up over 69 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, I

Phathom Pharmaceuticals (PHAT) stock rises as Cantor Fitzgerald issues an Overweight rating, rejecting its IP-rights related risk. Read more here.

Phathom Pharmaceuticals, Inc.'s vonoprazan received multiple approvals, but the stock price showed erratic behavior. Learn more on PHAT stock here.

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA ® (vonoprazan) Tablets

Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ETCompany ParticipantsEric Sciorilli - Head of...

Net Revenues: $16.4 million for Q3 2024, representing over 120% sequential quarter-over-quarter increase.Gross Profit: $14 million, with a gross margin of 86%,

Nov 07, 2024 / 01:30PM GMTOperator Hello and welcome to the Fathom Pharmaceuticals third quarter, 2024 earnings results call (operator instructions) I would lik

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 15.92% and 30.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly...

Swedish pharmaceutical company Orexo AB's nasal rescue medication OX124 is under FDA review, with a decision anticipated on July 15, 2024..

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

Gyre Therapeutics focuses on developing anti-inflammatory drugs for organ diseases, showing promising potential. Read more on GYRE stock here.

The prebiotic ingredients market is experiencing noteworthy growth, propelled by various factors such as the increasing demand for prebiotics as a key...

Although US stocks closed mixed on Tuesday, there were a few notable insider trades.

GuruFocus Article or News written by insider and the topic is about:

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.